Autophagy Maintenance (AUTOMAIN) Therapy in High-Grade Serous Ovarian Cancer: A Phase II Randomized Trial

Sponsor:

MUSC

Sponsor Study ID:

103919

CTO #:

103919

NCT Number:

NCT06971744

Phase:

II

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Ovary

Study Objectives:

To assess the safety of HCQ + NFV in combination with standard- of-care maintenance bevacizumab in patients with high-grade serous ovarian cancer. Evaluate the anti-tumor activity of HCQ + NFV in combination with standard-of-care maintenance bevacizumab in patients with high- grade serous ovarian cancer. To assess changes in CA125 in patients treated with HCQ + NFV in combination with standard-of-care maintenance bevacizumab. To assess changes in Quality of Life (QOL) in patients treated with HCQ + NFV in combination with standard-of-care maintenance bevacizumab.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)